在高胆固醇贫血的子体内进行血管造形术或支架植入后,互乐金-10可抑制内膜增生
L J Feldman1, L Aguirre, M Ziol
1U460 INSERM, Faculté Xavier Bichat, Paris, France.
Circulation
|March 1, 2000
概括
外源性互白素-10 (IL-10) 限制了血管造形术和支架后的内脏增生. 这种抗炎性细胞因子减少了内脏生长和巨细胞的透,这表明它有潜力预防静脉静脉缩.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 支架植入后的内极性增生是支架静止症的主要原因.
- 激活的单细胞对亲密生长至关重要.
- 介质素-10 (IL-10),一种抗炎性细胞因子,使单细胞失活,并且在动脉样硬化斑块中存在内源性.
研究的目的:
- 调查外源性IL-10可以减轻气球血管造形或支架后血管造形后的内脏增生症的假设.
主要方法:
- 高胆固醇贫血的子在血管造形术或支架后接受了复合人类IL-10 (rhuIL-10).
- 通过测量IL-1β释放来评估单细胞失活.
- 形态测量分析量化了亲密生长,巨细胞透和繁殖活动.
主要成果:
- rhuIL-10治疗导致持续高IL-10血清水平和单细胞失活.
- 在气球血管整形和支架植入后,内体生长减少了约50%.
- 在rhuIL-10治疗后,巨细胞透率降低了67%,增殖活性降低了81%.
- 微小的血细胞计数变化是唯一检测到的不良影响.
结论:
- 抗炎性细胞因子rhuIL-10有效地降低了受伤后的内脏增生症.
- rhuIL-10显著减弱了支架内密生长.
- 鲁伊尔-10的良好的毒性概况表明它在预防静脉静脉复缩方面具有潜在的治疗效用.
相关概念视频
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:27Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655